← Human Trials & Peer-Reviewed Studies
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
Plain-language guide to NCT06934642: early phase 1 interventional trial of Tirzepatide, 8 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06934642
- Phase
- early phase 1
- Status
- recruiting participants
- Start
- 2025-06-30
- Completion (planned or actual)
- 2026-10
- Participants
- 8 (estimated)
- Design
- na, open label (everyone knows who gets what), other
- Conditions studied
- MASLD; Obesity
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
This registered early phase 1 trial tested Tirzepatide.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease.
Tirzepatide is a medication used to treat type 2 diabetes and obesity.
It had 1 arm (groups): Intervention Arm (experimental).
Individuals in the intervention arm (only arm) will receive tirzepatide for 12 months.
The registry classes the interventions as drug.
Who Took Part
The registry lists 8 planned participants were the target.
It was open to people of any sex aged from 18 years up to 75 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Men and women. Diagnosis of MASLD based on the following criteria:. Presence of at least 1 out of the 5 following cardiometabolic criteria:. BMI \>25 kg/m2 OR waist circumference \>94 cm (men) or 80cm (women). Blood pressure \>130/85 mmHg OR specific antihypertensive drug treatment.
The full record lists 12 inclusion and 15 exclusion criteria; among the exclusions: pregnancy or breast feeding; premenopausal women not on any form of contraception; other identifiable causes of steatosis.
How the Study Was Run
Design: single-group and open-label.
Nothing was hidden in this open-label Tirzepatide study: the participants and staff both knew the treatment.
Everyone received the same intervention, so there was no separate comparison group inside the trial.
It started in 2025-06-30 with completion listed for 2026-10.
It ran at 1 site in United States.
Its stated primary purpose is other.
What Was Measured
It also tracked 4 secondary outcomes, for example Liver Fat Content, Liver Stiffness, Body weight and Metabolic markers.
What This Means in Plain Language
Put simply, this is a early phase 1 trial of Tirzepatide in 8 people.
Its size is small, so on its own it can only give an early look.
It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Tirzepatide compound page, all human trials.
Our Notes on the Compound
Tirzepatide: A prescription peptide medicine that acts on both the GIP and GLP-1 receptors; Mounjaro and Zepbound contain the same active ingredient.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.